Generalized prurigo nodularis with dramatic response to dupilumab treatment: A case report  

作　　者：Cagdas Boyvadoglu Huseyin Serhat Inaloz 

机构地区：[1]Department of Dermatology,University of Gaziantep Faculty of Medicine,Gaziantep 27270,Turkey

出　　处：《World Journal of Dermatology》2023年第1期1-6,共6页世界皮肤病学杂志

摘　　要：BACKGROUND Prurigo nodularis(PN)is a chronic condition characterized by a papulonodular pruriginous eruption of unknown aetiology.Currently,there are no medications for PN that the United States Food and Drug Administration has approved,which leads to very variable practices in the prescription of off-label treatments.Treatment of PN is based on clinical experience rather than controlled trials.We present our case of generalized PN,in which we had a dramatic response with dupilumab.CASE SUMMARY A 58-year-old female patient was admitted to our clinic with severe itchy,erythematous nodular lesions that were widespread all over her body,especially on the legs and back.It was learned that the patient's complaints started 4 years ago,and there was a significant increase in the lesions in the last period.Dermatological examination revealed diffuse firm erythematous excoriated nodular lesions all over the body.In the blood tests of the patient,serum Immunoglobulin E(IgE)was measured at 9330 IU/mL.The patient was diagnosed with generalized prurigo nodularis together with clinical and histopathological findings.Due to severe clinical findings and the presence of comorbidities,dupilumab treatment was planned for the patient.In the follow-up 4 mo later,it was observed that all nodular lesions healed with postinflammatory hypopigmentation.The IgE value decreased to 1500 IU/mL after 4 mo of dupilumab treatment.CONCLUSION Dupilumab treatment stands out as an effective and safe systemic treatment agent among existing systemic treatments.

关 键 词：Dupilumab Prurigo nodularis PRURITUS Immunoglobulin E Atopic dermatitis Case report 

分 类 号：R73[医药卫生—肿瘤]